Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.


Clinical Trial Description

The pharmacology research shows that Magnesium Isoglycyrrhizinate could significantly decrease the elevation of ALT and AST coursed by carbon tetrachloride, D-galactosamine and Thioacetamide. It could also significantly reduce the injury on the liver coursed by D-galacosamine and immunologic factors. Magnesium Isoglycyrrhizinate with strong anti-inflammatory effect could protect the liver cell and improve the liver function. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02734966
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact
Status Completed
Phase Phase 2
Start date December 2007
Completion date December 2011

See also
  Status Clinical Trial Phase
Recruiting NCT05517668 - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Phase 2
Recruiting NCT05060289 - A Prognostic Model for Drug-induced Liver Injury in China
Completed NCT03092817 - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Phase 3
Completed NCT03211208 - Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
Completed NCT02182167 - A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis Phase 2/Phase 3
Not yet recruiting NCT02061826 - Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA) N/A
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A
Not yet recruiting NCT03091608 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule N/A
Not yet recruiting NCT03091556 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill. N/A
Not yet recruiting NCT03091244 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule. N/A
Not yet recruiting NCT03060252 - Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill N/A
Not yet recruiting NCT03091218 - Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule. N/A
Completed NCT02407964 - A Retrospective Study on Drug Induced Liver Injury in China N/A
Active, not recruiting NCT05144217 - Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo Phase 2/Phase 3
Completed NCT01705041 - Preliminary Evaluation of a Point-Of-Care Liver Function Test N/A
Recruiting NCT02086708 - Ultrasound Method to Measure Fibrosis of the Liver in Children N/A
Recruiting NCT05465642 - Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
Completed NCT01434173 - Risk of Acute Liver Injury in Users of Antimicrobials N/A
Completed NCT05532345 - Discrimination of DILI and AIH by Artificial Intelligence
Completed NCT03602703 - Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs